Novel tumor marker GSTA1 for lung caner as well as screening method and application thereof

Abstract

The invention discloses a novel tumor marker GSTA1 for lung cancer as well as a screening method and application thereof, belonging to the field of molecular biology and medical science. The marker is characterized in that on the basis of the novel lung cancer specific binding polypeptide acquired by utilizing a bacteriophage random peptide library screening technology at the earlier stage, the polypeptide is used as a probe to select lung cancer associated antigen GSTA1 from a lung cancer cDNA library. The occurrence and development of the lung cancer have a complicated mechanism, the lung cancer involves to the alteration of a lot of lung cancer associated genes and expressions thereof in the primary stage, a plurality of adhesion molecules as well as receptors or ligands can be expressed in a patient body under the effect of a carcinogenic factor, the content of the marker released by the tumor at different development stages is also different, the variation of the specific molecular marker of the tumor cancer is detected from peripheral blood and sputum, advantages of simplicity, rapidness, little pain and easiness in reviewing can be achieved, the novel tumor marker GSTA1 is easy to receive by the patient, and an important significance on the clinical diagnosis for the lung cancer can be achieved. The molecular marker can be provided for the diagnosis and targeted therapy of the lung cancer, a candidate antigen can be provided for the research of the lung cancer tumor vaccine, and the application prospect is wide.

Description

Technical field [0001] The present invention involves the field of molecular labeling technology, and more specific, involves a new lung cancer tumor logo GSTA1 and its screening methods and applications. Background technique [0002] Lung cancer is currently one of the most common and the largest number of dead tumors in the world, and it is also the largest cancer in my country. Its incidence and mortality growth is the fastest.Due to the hidden disease of lung cancer, the diagnosis and treatment situation is far from satisfactory. The main reason is that the lack of early diagnosis and effective treatment methods.The symptoms of patients are mostly advanced, the prognosis is poor, the total five -year survival rate does not exceed 15%, and those with symptoms ≤10%.However, patients with early diagnosis of lung cancer, the prognosis of surgical treatment has been significantly improved compared to mid -to -advanced lung cancer, and its survival rate can reach 70%.It can be seen...

AI Technical Summary

Problems solved by technology

[0005] Although the above-mentioned tumor markers related to lung cancer have been found, most of these markers are non-organ-specific. They are not lung cancer-specific antigens, but tumor-related Substances exist not only in malignant tumors, but also in benign tumors, embryonic tissues, and even normal tissues. The diagnosis of lung cancer lacks specificity and has only reference value

On the other hand, due to the diversity of lung cancer histopathology, the heterogeneity of tumor cells of the same pathology, and the complexity and polymorphism of tumor biological behavior, the diagnostic value of single marker detection for lung cancer is limited, which can only reflect the Due to changes in certain aspects of the disease, many scholars at home and abroad tend to screen a variety of valuable tumor markers for joint detection in order to increase the positive rate of lung cancer diagnosis

Although it has become a consensus that combined detection is better than single detection, not any combination can improve the positive rate of clinical diagnosis, and the conclusions on the best combination are quite inconsistent, and even the opposite results

Images